Abstract:Background: KCa3.1 channels are calcium/calmodulin-regulated voltage-independent K(+) channels that produce membrane hyperpolarization and shape Ca(2+)-signaling and thereby physiological functions in epithelia, blood vessels, and white and red blood cells. Up-regulation of KCa3.1 is evident in fibrotic and inflamed tissues and some tumors rendering the channel a potential drug target. In the present study, we searched for novel potent small molecule inhibitors of KCa3.1 by testing a series of 20 selected natural and synthetic (poly)phenols, synthetic benzoic acids, and non-steroidal anti-inflammatory drugs (NSAIDs), with known cytoprotective, anti-inflammatory, and/or cytostatic activities. Methodology/principal findings: In electrophysiological experiments, we identified the natural phenols, caffeic acid (EC50 1.3 µM) and resveratrol (EC50 10 µM) as KCa3.1 inhibitors with moderate potency. The phenols, vanillic acid, gallic acid, and hydroxytyrosol had weak or no blocking effects. Out of the NSAIDs, flufenamic acid was moderately potent (EC50 1.6 µM), followed by mesalamine (EC50≥10 µM). The synthetic fluoro-trivanillic ester, 13b ([3,5-bis[(3-fluoro-4-hydroxy-benzoyl)oxymethyl]phenyl]methyl 3-fluoro-4-hydroxy-benzoate), was identified as a potent mixed KCa2/3 channel inhibitor with an EC50 of 19 nM for KCa3.1 and 360 pM for KCa2.3, which affected KCa1.1 and Kv channels only at micromolar concentrations. The KCa3.1/KCa2-activator SKA-31 antagonized the 13b-blockade. In proliferation assays, 13b was not cytotoxic and reduced proliferation of 3T3 fibroblasts as well as caffeic acid. In isometric vessel myography, 13b increased contractions of porcine coronary arteries to serotonin and antagonized endothelium-derived hyperpolarization-mediated vasorelaxation to pharmacological KCa3.1/KCa2.3 activation. Conclusions/significance: We identified the natural phenols, caffeic acid and resveratrol, the NSAID, flufenamic acid, and the polyphenol 13b as novel KCa3.1 inhibitors. The high potency of 13b with pan-activity on KCa3.1/KCa2 channels makes 13b a new pharmacological tool to manipulate inflammation and cancer growth through KCa3.1/KCa2 blockade and a promising template for new drug design.

Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore

Building KCNQ1/KCNE1 Channel Models and Probing Their Interactions by Molecular-Dynamics Simulations.

Structural bases of inhibitory mechanism of CaV1.2 channel inhibitors

Characterization of Binding Site of Closed-State KCNQ1 Potassium Channel by Homology Modeling, Molecular Docking, and Pharmacophore Identification

Mechanisms and Energetics of Potassium Channel Block by Local Anesthetics and Antifungal Agents.

Structural Basis for the Modulation of Human KCNQ4 by Small-Molecule Drugs

Structural insights into binding of therapeutic channel blockers in NMDA receptors

Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3

Atomistic mechanisms of the regulation of small-conductance Ca2+-activated K+ channel (SK2) by PIP2

Structural Mechanisms for the Activation of Human Cardiac KCNQ1 Channel by Electro-Mechanical Coupling Enhancers

Molecular Basis for Ligand Modulation of a Mammalian Voltage-Gated Ca2+ Channel

Molecular Basis for Ligand Activation of the Human KCNQ2 Channel.

A Small-Molecule Activation Mechanism That Directly Opens the KCNQ2 Channel

Identification and Optimization of 2‐aminobenzimidazole Derivatives As Novel Inhibitors of TRPC4 and TRPC5 Channels

Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugs

Isoform-specific Prolongation of Kv7 (KCNQ) Potassium Channel Opening Mediated by New Molecular Determinants for Drug-Channel Interactions

Pharmacophore Mapping for Kv1.5 Potassium Channel Blockers

Structural modeling of hERG channel-drug interactions using Rosetta

Structural Insights into the Lipid and Ligand Regulation of a Human Neuronal KCNQ Channel

Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing.

Molecular determinants of KCNQ1 channel block by a benzodiazepine.